p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) have been proposed as prognostic markers for early breast cancer (BC), although their relationship with conventional parameters and patient prognosis, as well as their distribution within the molecular BC subtypes remains uncertain. Patients and Methods: In this observational study, we analyzed the immunohistochemical expression of p53 and BLC2 in 1099 early BC patients surgically treated between 2000 and 2006 and followed for at least 5 years, also considering their association with pathologic factors and molecular subtypes, as well as their influence on disease-free survival. Results: p53 and BLC2 are distributed differently across molecular subtypes (P < .0001); in particular, p53 positivity and BLC2 negativity seems to be associated with more aggressive conventional tumor phenotypes. Moreover, BLC2 negativity seems to be a significant discriminating factor for disease-free survival (P = .003) according to Kaplan-Meier analysis, while p53 seems to have no discriminating effect. Among patients with discordant p53/BLC2 phenotype, the combination p53+BLC2 seems to be associated with the worst outcomes (P = .007) and significantly influenced the clinical course of node-negative patients treated only with hormone therapy (P = .004). Conclusion: These two biomarkers, in addition to conventional pathologic factors and molecular subtype, could help define the risk and outcome of BC. Management of early breast cancer (BC) is complicated by the limited number of clinicopathologic prognostic factors available. We analyzed p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) immunohistochemistry expression in 1099 early BC patients. p53 and BLC2 are distributed differently across BC molecular subtypes; p53-positive/BLC2-negative BC corresponds to more aggressive phenotypes. p53 and BLC2 could help define the risk and outcome of BC in addition to molecular subtypes.

Original languageEnglish
Pages (from-to)e761-e770
JournalClinical Breast Cancer
Volume20
Issue number6
DOIs
Publication statusPublished - Dec 2020

Keywords

  • Immunohistochemistry
  • Individualized medicine
  • Prognosis
  • Prognostic factors
  • TP53

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study'. Together they form a unique fingerprint.

Cite this